Enovis Corporation (NYSE:ENOV) Stock Has Average Target Price of $39.50 According to Analysts

Enovis Corporation (NYSE:ENOV) has received an average rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $39.50.

A number of research analysts recently commented on the company. Citizens Jmp dropped their price target on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 2nd. Wells Fargo & Company decreased their target price on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, September 2nd. BMO Capital Markets set a $27.00 target price on shares of Enovis in a report on Tuesday, September 1st. Citigroup restated a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Finally, Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday.

Enovis Price Performance

Shares of NYSE ENOV opened at $17.72 on Wednesday. The stock has a market capitalization of $1.02 billion, a PE ratio of -0.92 and a beta of 1.37. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The business has a fifty day moving average price of $21.74 and a two-hundred day moving average price of $23.29. Enovis has a fifty-two week low of $16.70 and a fifty-two week high of $34.28.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same period in the prior year, the company posted $0.79 EPS. The company’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert bought 5,140 shares of Enovis stock in a transaction on Thursday, September 3rd. The shares were purchased at an average price of $19.46 per share, with a total value of $100,024.40. Following the acquisition, the insider owned 61,238 shares in the company, valued at $1,191,691.48. This trade represents a 9.16% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. This represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 23,293 shares of company stock valued at $449,599. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Several institutional investors and hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new position in Enovis in the second quarter valued at about $39,000. IFP Advisors Inc lifted its holdings in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after acquiring an additional 1,174 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Enovis by 59.7% in the second quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock worth $36,000 after acquiring an additional 652 shares during the last quarter. Amundi boosted its stake in shares of Enovis by 397.7% in the 2nd quarter. Amundi now owns 369,189 shares of the company’s stock valued at $7,642,000 after purchasing an additional 295,005 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Enovis in the 2nd quarter valued at approximately $559,000. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.